Cargando…
A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
BACKGROUND: Aggressive lipid lowering with high doses of statins increases the risk of statin-induced myopathy. However, the cellular mechanisms leading to muscle damage are not known and sensitive biomarkers are needed to identify patients at risk of developing statin-induced serious side effects....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762369/ https://www.ncbi.nlm.nih.gov/pubmed/17183729 http://dx.doi.org/10.1371/journal.pone.0000097 |
_version_ | 1782131552878067712 |
---|---|
author | Laaksonen, Reijo Katajamaa, Mikko Päivä, Hannu Sysi-Aho, Marko Saarinen, Lilli Junni, Päivi Lütjohann, Dieter Smet, Joél Van Coster, Rudy Seppänen-Laakso, Tuulikki Lehtimäki, Terho Soini, Juhani Orešič, Matej |
author_facet | Laaksonen, Reijo Katajamaa, Mikko Päivä, Hannu Sysi-Aho, Marko Saarinen, Lilli Junni, Päivi Lütjohann, Dieter Smet, Joél Van Coster, Rudy Seppänen-Laakso, Tuulikki Lehtimäki, Terho Soini, Juhani Orešič, Matej |
author_sort | Laaksonen, Reijo |
collection | PubMed |
description | BACKGROUND: Aggressive lipid lowering with high doses of statins increases the risk of statin-induced myopathy. However, the cellular mechanisms leading to muscle damage are not known and sensitive biomarkers are needed to identify patients at risk of developing statin-induced serious side effects. METHODOLOGY: We performed bioinformatics analysis of whole genome expression profiling of muscle specimens and UPLC/MS based lipidomics analyses of plasma samples obtained in an earlier randomized trial from patients either on high dose simvastatin (80 mg), atorvastatin (40 mg), or placebo. PRINCIPAL FINDINGS: High dose simvastatin treatment resulted in 111 differentially expressed genes (1.5-fold change and p-value<0.05), while expression of only one and five genes was altered in the placebo and atorvastatin groups, respectively. The Gene Set Enrichment Analysis identified several affected pathways (23 gene lists with False Discovery Rate q-value<0.1) in muscle following high dose simvastatin, including eicosanoid synthesis and Phospholipase C pathways. Using lipidomic analysis we identified previously uncharacterized drug-specific changes in the plasma lipid profile despite similar statin-induced changes in plasma LDL-cholesterol. We also found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. CONCLUSIONS: High dose simvastatin affects multiple metabolic and signaling pathways in skeletal muscle, including the pro-inflammatory pathways. Thus, our results demonstrate that clinically used high statin dosages may lead to unexpected metabolic effects in non-hepatic tissues. The lipidomic profiles may serve as highly sensitive biomarkers of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity. |
format | Text |
id | pubmed-1762369 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-17623692007-01-04 A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle Laaksonen, Reijo Katajamaa, Mikko Päivä, Hannu Sysi-Aho, Marko Saarinen, Lilli Junni, Päivi Lütjohann, Dieter Smet, Joél Van Coster, Rudy Seppänen-Laakso, Tuulikki Lehtimäki, Terho Soini, Juhani Orešič, Matej PLoS One Research Article BACKGROUND: Aggressive lipid lowering with high doses of statins increases the risk of statin-induced myopathy. However, the cellular mechanisms leading to muscle damage are not known and sensitive biomarkers are needed to identify patients at risk of developing statin-induced serious side effects. METHODOLOGY: We performed bioinformatics analysis of whole genome expression profiling of muscle specimens and UPLC/MS based lipidomics analyses of plasma samples obtained in an earlier randomized trial from patients either on high dose simvastatin (80 mg), atorvastatin (40 mg), or placebo. PRINCIPAL FINDINGS: High dose simvastatin treatment resulted in 111 differentially expressed genes (1.5-fold change and p-value<0.05), while expression of only one and five genes was altered in the placebo and atorvastatin groups, respectively. The Gene Set Enrichment Analysis identified several affected pathways (23 gene lists with False Discovery Rate q-value<0.1) in muscle following high dose simvastatin, including eicosanoid synthesis and Phospholipase C pathways. Using lipidomic analysis we identified previously uncharacterized drug-specific changes in the plasma lipid profile despite similar statin-induced changes in plasma LDL-cholesterol. We also found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. CONCLUSIONS: High dose simvastatin affects multiple metabolic and signaling pathways in skeletal muscle, including the pro-inflammatory pathways. Thus, our results demonstrate that clinically used high statin dosages may lead to unexpected metabolic effects in non-hepatic tissues. The lipidomic profiles may serve as highly sensitive biomarkers of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity. Public Library of Science 2006-12-20 /pmc/articles/PMC1762369/ /pubmed/17183729 http://dx.doi.org/10.1371/journal.pone.0000097 Text en Laaksonen et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Laaksonen, Reijo Katajamaa, Mikko Päivä, Hannu Sysi-Aho, Marko Saarinen, Lilli Junni, Päivi Lütjohann, Dieter Smet, Joél Van Coster, Rudy Seppänen-Laakso, Tuulikki Lehtimäki, Terho Soini, Juhani Orešič, Matej A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle |
title | A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle |
title_full | A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle |
title_fullStr | A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle |
title_full_unstemmed | A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle |
title_short | A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle |
title_sort | systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762369/ https://www.ncbi.nlm.nih.gov/pubmed/17183729 http://dx.doi.org/10.1371/journal.pone.0000097 |
work_keys_str_mv | AT laaksonenreijo asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT katajamaamikko asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT paivahannu asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT sysiahomarko asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT saarinenlilli asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT junnipaivi asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT lutjohanndieter asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT smetjoel asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT vancosterrudy asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT seppanenlaaksotuulikki asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT lehtimakiterho asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT soinijuhani asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT oresicmatej asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT laaksonenreijo systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT katajamaamikko systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT paivahannu systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT sysiahomarko systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT saarinenlilli systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT junnipaivi systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT lutjohanndieter systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT smetjoel systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT vancosterrudy systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT seppanenlaaksotuulikki systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT lehtimakiterho systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT soinijuhani systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle AT oresicmatej systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle |